Xiao Hong Hu

US Patent:

20200261463, Aug 20, 2020

Filed:

Feb 21, 2020

Appl. No.:

16/797104

Inventors:

- Ann Arbor MI, US
Xiao Hu - Northville MI, US
H. Jeffrey Wilkins - Sellersville PA, US

International Classification:

A61K 31/538
A61P 35/04

Abstract:

The invention provides methods for treating a cancer selected from the group consisting of (i) a squamous cell carcinoma located in a patient's head and/or neck and (ii) a urothelial carcinoma using aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide compounds.

US Patent:

20180179224, Jun 28, 2018

Filed:

Oct 11, 2017

Appl. No.:

15/729910

Inventors:

- Ann Arbor MI, US
Peter L. Toogood - Ann Arbor MI, US
Xiao Hu - Northville MI, US

International Classification:

C07D 498/04
C07D 471/04
C07D 491/052

Abstract:

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORy activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

US Patent:

20170007686, Jan 12, 2017

Filed:

Feb 27, 2015

Appl. No.:

15/120798

Inventors:

- Ann Arbor MI, US
Peter L. Toogood - Ann Arbor MI, US
Xiao Hu - Northville MI, US
Thomas D. Aicher - Ann Arbor MI, US
Laura Lee Celeste - Ann Arbor MI, US
Xikui Liu - Ann Arbor MI, US
Clarke B. Taylor - Ann Arbor MI, US
Chad A. Van Huis - Hartland MI, US

International Classification:

A61K 39/00
A61K 31/4353
A61K 31/4375
C12N 5/0783
A61K 31/538
A61K 31/4709
A61K 31/47
A61K 39/02
A61K 31/437

Abstract:

The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) and provides adoptive cellular therapies using an agonist of RORγ, populations of lymphocyte cells that have been exposed to an agonist of RORγ, populations of dendritic cells that have been exposed to an agonist of RORγ, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of RORγ to a patient.

US Patent:

20160318951, Nov 3, 2016

Filed:

Jul 8, 2016

Appl. No.:

15/205212

Inventors:

- Ann Arbor MI, US
Peter L. Toogood - Ann Arbor MI, US
Xiao Hu - Northville MI, US

International Classification:

C07D 498/04
C07D 471/04

Abstract:

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

US Patent:

20150133437, May 14, 2015

Filed:

May 8, 2013

Appl. No.:

14/398774

Inventors:

- Ann Arbor MI, US
Peter L. Toogood - Ann Arbor MI, US
Xiao Hu - Northville MI, US

International Classification:

C07D 498/04
C07D 471/04

US Classification:

514221, 546122, 514300, 544105, 5142305, 540568

Abstract:

The invention provides tetrahydro[1,8]naphthyridine and related compounds, methods of promoting RORy activity and/or increasing the amount of iL-17 in a subject, and therapeutic uses of the tetrahydro[1,8]naphthyridine and related compounds. In particular, the invention provides sulfonamide-tetrahydro[1,8]naphthyridine and related compounds, methods of using such compounds to promote RORy activity and/or increase the amount of iL-17 in a subject, and treat medical conditions in which activation of immune response would be beneficial such as in cancer and infections.